Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials
Kyverna Therapeutics aims to be the fifth biotech to IPO in 2024 as the autoimmune CAR-T cell therapy maker sets its sights on $182 million in net proceeds from a listing as “KYTX.”
If the California biotech follows through with its Nasdaq listing before Valentine’s Day, as Endpoints News reported last month, it would come as momentum builds in the industry for a return to the public markets. CG Oncology and ArriVent kicked things off last week with upsized offerings and strong first days. Alto Neuroscience and Fractyl Health are expected to float in the coming days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
